latest update:
[TrialBase DB]

trial summary · NCT07856797

A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

A Prospective, Open-Label, Multicenter, Post-Market Clinical Follow-Up Study to Confirm the Long-term Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

Trial record from the TrialBase DB dataset, status RECRUITING, condition Nasolabial Folds, sponsored by Merz North America, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07856797phase —enrollment 163start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to confirm the long-term safety, effectiveness, and degradation profile of RADIESSE® Injectable Implant for the correction of moderate to severe nasolabial folds (NLFs) in Chinese adults. Eligible participants will receive treatment with RADIESSE® Injectable Implant in both NLFs and may receive an optional touch-up treatment at Month 1 at investigator's discretion. Participants will be followed for up to 24 months after last treatment.

Source record: https://clinicaltrials.gov/study/NCT07856797

Facts

registry idNCT07856797
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionNasolabial Folds
sponsorMerz North America, Inc.
sponsor classINDUSTRY
enrollment163
start date2026-10-27
primary completion2027-08
completion2029-02
results postednot reported

Conditions

  • Nasolabial Folds

Interventions

  • Subdermal Implant

Countries

  • China

Intervention types: DEVICE

Work with this record